Are community oncology practices with or without clinical research programs different? A comparison of patient and practice characteristics
JNCI Cancer Spectrum · 2024
DOI: 10.1093/jncics/pkae060 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift JNCI Cancer Spectrum, 2024. Verfasst von Ivy Altomare und 7 weiteren Autor:innen. Beteiligte Einrichtung: Flatiron Health, Inc, New York, NY, USA. Hauptthemen laut MEDLINE: Medical Oncology, Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Flatiron Health, Inc.
Abstract (Originalsprache)
Background
Expanding access to clinical trials in community settings is a potential approach to addressing disparities in accrual of historically underrepresented populations. However, little is known about the characteristics of practices that do not participate in research. We investigated differences in patient and practice characteristics of US community oncology practices with high vs low engagement in clinical research.
Methods
We included patients from a real-world, nationwide electronic health record–derived, de-identified database who received active treatment for cancer at community oncology practices between November 1, 2017, and October 31, 2022. We assessed patient and practice characteristics and their associations with high vs low research engagement using descriptive analyses and logistic regression models.
Results
Of the 178 practices, 70 (39.3%) events had high research engagement, treated 57.8% of the overall 568 540 patient cohort, and enrolled 3.25% of their patients on cancer treatment trials during the 5-year observation period (vs 0.27% enrollment among low engagement practices). Practices with low vs high research engagement treated higher proportions of the following patient groups: ages 75 years and older (24.2% vs 21.8%), non-Latinx Black (12.6% vs 10.3%) or Latinx (11.6% vs 6.1%), were within the lowest socioeconomic status quintile (21.9% vs16.5%), and were uninsured or had no documented insurance (22.2% vs 13.6%).
Conclusions
Patient groups historically underrepresented in oncology clinical trials are more likely to be treated at community practices with limited or no access to trials. These results suggest that investments to expand the clinical research footprint among practices with low research engagement could help address persistent inequities in trial representation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Flatiron Health, Inc, New York, NY, USA.
- School of Public Health, Division of Health Policy and Management, University of California, Berkeley, Berkeley, CA, USA.
- Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, US.
ORCID-Profile: Ivy Altomare, Xiaoliang Wang, Maneet Kaur, Jenny S Guadamuz, Sam Falk, Forrest Xiao
Förderung
- Flatiron Health, Inc
Zitieren
APA
Altomare, I., Wang, X., Kaur, M., Guadamuz, J. S., Falk, S., Xiao, F., Meropol, N. J., & Zhao, Y. (2024). Are community oncology practices with or without clinical research programs different? A comparison of patient and practice characteristics. JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkae060
Vancouver
Altomare I, Wang X, Kaur M, Guadamuz JS, Falk S, Xiao F, et al. Are community oncology practices with or without clinical research programs different? A comparison of patient and practice characteristics. JNCI Cancer Spectrum. 2024. doi:10.1093/jncics/pkae060
BibTeX
@article{Altomare2024,
author = {Altomare, Ivy and Wang, Xiaoliang and Kaur, Maneet and Guadamuz, Jenny S and Falk, Sam and Xiao, Forrest and Meropol, Neal J and Zhao, Yihua},
title = {Are community oncology practices with or without clinical research programs different? A comparison of patient and practice characteristics},
journal = {JNCI Cancer Spectrum},
year = {2024},
doi = {10.1093/jncics/pkae060}
}
EUVIMED